Skip to main contentSkip to navigation
Sirius Investors

ACARIX.ST Stock: Acarix AB (publ) Stock Price, Analysis & Insights

Get live ACARIX.ST stock price $0.26, comprehensive Acarix AB (publ) stock analysis, charts, news, and expert forecast. Real-time ACARIX.ST stock data and investment insights.

0.26
3.03%Today
ACARIX.STAcarix AB (publ) • Stockholm Stock Exchange • Healthcare
Market Cap
287.57M
Volume
1.25M
52W High
0.47
52W Low
0.22

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADSc...

Company Information

CEO
Aamir Mahmood
Sector
Healthcare
Industry
Medical - Devices
Employees
8

Contact Information

Address
Jungmansgatan 12
Country
SE

Investment Analysis & Business Insights

Healthcare
Medical - Devices

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: -0.21) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Acarix AB (publ) shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Acarix AB (publ)
  • Investors should consider how Acarix AB (publ) fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

287.57M

P/E Ratio (TTM)

-6.40

Beta

-0.21

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

43/100 ⭐⭐⭐

Overall
-1.0%
NYSE
-1.6%
NASDAQ
-0.4%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.3%+1.9%19.8
83/100⭐⭐⭐⭐⭐
Technology+0.8%+1.1%+3.0%52.0
76/100⭐⭐⭐⭐⭐
Basic Materials+0.8%+0.3%+1.9%27.9
69/100⭐⭐⭐⭐
Industrials-0.3%-0.9%+2.7%43.0
64/100⭐⭐⭐⭐
Communication Services-0.8%-1.3%+0.4%21.9
48/100⭐⭐⭐
Consumer Defensive+0.6%+1.6%-2.5%31.2
44/100⭐⭐⭐
Healthcare-1.0%-2.0%+1.5%30.5
43/100⭐⭐⭐
Real Estate+0.5%-1.1%-0.0%50.0
33/100⭐⭐
Energy+0.5%-3.6%-0.0%35.9
31/100⭐⭐
Utilities+2.0%-1.3%-5.1%26.1
31/100⭐⭐
Consumer Cyclical-0.3%+0.3%-0.2%55.8
28/100⭐⭐

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.